Personalized mRNA vaccine aims to train immune system against ovarian cancer

NCT ID NCT07676890

Not yet recruiting Disease control Sponsor: West China Hospital Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This trial tests a personalized mRNA vaccine called NeoOVIV in people with stage II or III ovarian cancer who have had surgery. The vaccine is designed to teach the immune system to recognize and attack cancer cells. Participants receive the vaccine alongside standard chemotherapy and an immunotherapy drug. The main goals are to check safety and see if the vaccine triggers an immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NeoOVIV (personalized mRNA-lipid nanoparticle vaccine)
What this could lead to: If successful, this could point toward a new way to use the immune system to fight ovarian cancer and reduce the risk of recurrence.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not effectiveness. The vaccine may cause side effects or fail to trigger a strong immune response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer ovarian carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MRNA VACCINE OVARIAN CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.